A case of acute kidney injury due to suspected omadacycline

Published on Mar. 24, 2025Total Views: 204 times Total Downloads: 48 times Download Mobile

Author: LIN Huan ^1, ² YU Xiuheng ² HUANG Xiaobin ³  ZHAO Yu ²

Affiliation: 1. School of Pharmaceutical Sciences, Chongqing Medical University, Chongqing 400016, China 2. Department of Pharmacy, University-Town Hospital of Chongqing Medical University, Chongqing 401331, China 3. Department of General Medicine, University-Town Hospital of Chongqing Medical University, Chongqing 401331, China

Keywords: Omadacycline Acute kidney injury Adverse drug reaction Case report

DOI: 10.12173/j.issn.1005-0698.202412137

Reference: LIN Huan, YU Xiuheng, HUANG Xiaobin, ZHAO Yu. A case of acute kidney injury due to suspected omadacycline[J]. Yaowu Liuxingbingxue Zazhi, 2025, 34(3): 353-358. DOI: 10.12173/j.issn.1005-0698.202412137.[Article in Chinese]  Copied

Abstract
Full-text
References

Abstract

An 81-year-old female patient was treated with anti-infective therapy of omadacycline for a soft-tissue skin infection, and developed acute kidney injury (AKI) 6 d after the administration of omadacycline. Laboratory tests showed that the urea was 6.11 mmol·L^-1, the creatinine was 236.40 μmol·L^-1, and the glomerular filtration rate was 18.18 mL·min^-1·(1.73m²)^- 1, which led to the definitive diagnosis of AKI. The association score of the suspected drug using Naranjo's Assessment Scale suggests that the patient's adverse reaction of AKI was suspected to be caused by omadacycline. After stopping omadacycline, the patient's renal function indicators gradually recovered after symptomatic treatment with renal protection and continuous blood purification. This paper discussed the occurrence mechanism and treatment prognosis of AKI caused by omadacycline. It suggestd that clinical use of omadacycline should be alert to the adverse effects of renal injury, and timely medication analysis and symptomatic treatment should be carried out to ensure the safety and effectiveness of treatment.

Full-text

Please download the PDF version to read the full text: download

References

1.Dougherty JA, Sucher AJ, Chahine EB, et al. Omadacycline: a new tetracycline antibiotic[J]. Ann Pharmacother, 2019, 53(5): 486-500. DOI: 10.1177/1060028018818094.

2.Zhanel GG, Esquivel J, Zelenitsky S, et al. Omadacycline: a novel oral and intravenous aminomethylcycline antibiotic agent[J]. Drugs, 2020, 80(3): 285-313. DOI: 10.1007/s40265-020-01257-4.

3.陈明毅, 唐可京, 陈杰. 奥马环素在特殊人群、特殊病理状态患者中应用研究进展[J]. 中国新药杂志, 2023, 32(22): 2300-2305. [Chen MY, Tang KJ, Chen J. Progress in research on application of omadacycline in special population and patients with special pathological status[J]. Chinese Journal of New Drugs, 2023, 32(22): 2300-2305.] DOI: 10.3969/j.issn.1003-3734.2023.22.012.

4.Durães F, Sousa E. Omadacycline: a newly approved antibacterial from the class of tetracyclines[J]. Pharmaceuticals (Basel), 2019, 12(2): 63. DOI: 10.3390/ph12020063.

5.蔡乐, 张婧, 伏安, 等. 基于FDA不良事件报告系统数据库的奥马环素不良事件信号挖掘[J]. 临床药物治疗杂志, 2023, 21(7): 65-70. [Cai L, Zhang J, Fu A, et al. Data-mining and analysis of adverse events signals for omacycline based on FDA adverse event reporting system database[J]. Clinical Medication Journal, 2023, 21(7): 65-70.] DOI: 10.3969/j.issn.1672-3384. 2023.07.013.

6.魏戌, 谢雁鸣. 国内外不良反应因果判断原则及评价方法解读[J]. 中国中药杂志, 2012, 37(18): 2744-2747. [Wei X, Xie YM. Principle of adverse drug reaction causality judgement interpretation of causality assessment method both in China and abroad[J]. China Journal of Chinese Materia Medica, 2012, 37(18): 2744-2747.] DOI: 10.4268/cjcmm20121819.

7.Gholami F, Sadeghi M, Zakariaei Z, et al. Rhabdomyolysis and acute kidney injury due to suicide attempt with tramadol: a rare case report[J]. Clin Case Rep, 2022, 10(1): e05255. DOI: 10.1002/ccr3.5255.

8.吴冰, 陈世耀. 替加环素致肌酐水平升高1例[J]. 中国药物应用与监测, 2014, 11(4): 253-254. [Wu B, Chen SY. One case of elevated creatinine induced by tigecycline[J]. Chinese Journal of Drug Application and Monitoring, 2014, 11(4): 253-254.] https://wenku.baidu.com/view/42d4ca56d15abe23482f4de7?fr=xueshu&_wkts_=1742202083290&needWelcomeRecommand=1.

9.Esteban-Molina A, Royo-Álvarez M, Araujo-Aguilar P, et al. Azotemia induced by tigecycline[J]. Enferm Infecc Microbiol Clin (Engl ed), 2022, 40(8): 461-463. DOI: 10.1016/j.eimce.2022.05.002.

10.梁碧怡, 杨惠霞, 黄小梅, 等. 3种第三代四环素类抗菌药物ADE信号的挖掘与分析[J]. 中国药房, 2024, 35(9): 1123-1128. [Liang BY, Yang HX, Huang XM, et al. Data mining and analysis for ADE signals of three third-generation tetracycline antibiotics[J]. China Pharmacy, 2024, 35(9): 1123-1128.] DOI: 10.6039/j.issn.1001-0408.2024.09.17.

11.周晏曲, 费皓天, 汪成亮, 等. 基于FAERS的未成年人使用四环素类药物的安全性[J/OL]. 医药导报, 2024: 1-16. [Zhou YQ, Fei HT, Wang CL, et al. Study on the safety of tetracyclines in children based on the FAERS database[J/OL]. Herald of Medicine, 2024: 1-16.] http://kns.cnki.net/kcms/detail/42.1293.R.20240919.1202.004.html.

12.杨磊, 王林海, 林意菊, 等. 1例肺癌患者顺铂胸腔灌注化疗引起急性肾功能损伤的病例分析[J]. 中国药物应用与监测, 2016, 13(4): 255-258. [Yang L, Wang LH, Lin YJ, et al. One case of acute renal injury caused by pleural infusion of cisplatin chemotherapy in lung cancer patient[J]. Chinese Journal of Drug Application and Monitoring, 2016, 13(4): 255-258.] https://d.wanfangdata.com.cn/periodical/Ch9QZXJpb2RpY2FsQ0hJTmV3UzIwMjUwMTE2MTYzNjE0EhJ6Z3l3eXl5amMyMDE2MDQwMTYaCDIzeHVidG1r.

13.Naranjo CA, Shear NH, Lanctôt KL. Advances in the diagnosis of adverse drug reactions[J]. J Clin Pharmacol, 1992, 32(10): 897-904. DOI: 10.1002/j.1552-4604.1992.tb04635.x.

14.Kellum JA, Lameire N, KDIGO AKI Guideline Work Group. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)[J]. Crit Care, 2013, 17(1): 204. DOI: 10.1186/cc11454.

15.俞雷. 警惕四环素族药物引起的肾损害[J]. 中国临床医生, 2007, 35(7): 59-60. [Yu L. Be wary of kidney damage caused by tetracycline family drugs[J]. Chinese Journal for Clinicians, 2007, 35(7): 59-60.] DOI: 10.3969/j.issn.1008-1089.2007.07.025.

16.Dong Z, Abbas MN, Kausar S, et al. Biological functions and molecular mechanisms of antibiotic tigecycline in the treatment of cancers[J]. Int J Mol Sci, 2019, 20(14): 3577. DOI: 10.3390/ijms20143577.

17.Elgazzar D, Aboubakr M, Bayoumi H, et al. Tigecycline and gentamicin-combined treatment enhances renal damage: oxidative stress, inflammatory reaction, and apoptosis interplay[J]. Pharmaceuticals, 2022, 15(6): 736. DOI: 10.3390/ph15060736.

18.Priya Dharshini LC, Vishnupriya S, Sakthivel KM, et al. Oxidative stress responsive transcription factors in cellular signalling transduction mechanisms[J]. Cell Signal, 2020, 72: 109670. DOI: 10.1016/j.cellsig.2020.109670.

19.Mike TB, DeVault H, Blackford MG. Acute tramadol ingestion with transient acute kidney injury in an adolescent female[J]. J Pediatr Pharmacol Ther, 2021, 26(4): 411-413. DOI: 10.5863/1551-6776-26.4.411.

20.Rodvold KA, Burgos RM, Tan X, et al. Omadacycline: a review of the clinical pharmacokinetics and pharmacodynamics[J]. Clin Pharmacokinet, 2020, 59(4): 409-425. DOI: 10.1007/s40262-019-00843-4.

21.Perazella MA, Rosner MH. Drug-induced acute kidney injury[J]. Clin J Am Soc Nephrol, 2022, 17(8): 1220-1233. DOI: 10.2215/CJN.11290821.

22.刘小明, 吴广礼, 黄旭东, 等. 老年急性肾损伤的临床特点及预后危险因素分析[J]. 临床误诊误治, 2018, 31(3): 99-102. [Liu XM, Wu GL, Huang XD, et al. Clinical characteristics and prognostic risk factors of elderly patients with acute kidney injury[J]. Clinical Misdiagnosis & Mistherapy, 2018, 31(3): 99-102.] DOI: 10.3969/j.issn.1002-3429.2018.03.030.

23.Berg JK, Tzanis E, Garrity-Ryan L, et al. Pharmacokinetics and safety of omadacycline in subjects with impaired renal function[J]. Antimicrob Agents Chemother, 2018, 62(2): e02057-17. DOI: 10.1128/AAC.02057-17.